188 related articles for article (PubMed ID: 31841002)
1. Antibody Fragment F(ab')
Li Q; Peterson N; Hanna RN; Kuszpit K; White J; Allen KL; Barnes A; Rickert KW; Shan L; Wu H; Dall'Acqua WF; Tsui P; Borrok MJ
Mol Pharm; 2020 Feb; 17(2):507-516. PubMed ID: 31841002
[TBL] [Abstract][Full Text] [Related]
2. Preparation, characterization, and in vivo biodistribution properties of synthetically cross-linked multivalent antitumor antibody fragments.
Schott ME; Frazier KA; Pollock DK; Verbanac KM
Bioconjug Chem; 1993; 4(2):153-65. PubMed ID: 7873647
[TBL] [Abstract][Full Text] [Related]
3. Biodistribution and planar gamma camera imaging of (123)I- and (131)I-labeled F(ab')(2) and Fab fragments of monoclonal antibody 14C5 in nude mice bearing an A549 lung tumor.
Burvenich IJ; Schoonooghe S; Blanckaert P; Bacher K; Vervoort L; Coene E; Mertens N; De Vos F; Slegers G
Nucl Med Biol; 2007 Apr; 34(3):257-65. PubMed ID: 17383575
[TBL] [Abstract][Full Text] [Related]
4. Optimization of IGF-1R SPECT/CT imaging using 111In-labeled F(ab')2 and Fab fragments of the monoclonal antibody R1507.
Heskamp S; van Laarhoven HW; Molkenboer-Kuenen JD; Bouwman WH; van der Graaf WT; Oyen WJ; Boerman OC
Mol Pharm; 2012 Aug; 9(8):2314-21. PubMed ID: 22747077
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibody Fab' fragment cross-linking using equilibrium transfer alkylation reagents. A strategy for site-specific conjugation of diagnostic and therapeutic agents with F(ab')2 fragments.
Wilbur DS; Stray JE; Hamlin DK; Curtis DK; Vessella RL
Bioconjug Chem; 1994; 5(3):220-35. PubMed ID: 7918742
[TBL] [Abstract][Full Text] [Related]
6. Valency of CD3 binding and internalization of the CD3 cell-surface complex control T cell responses to second signals: distinction between effects on protein kinase C, cytoplasmic free calcium, and proliferation.
Ledbetter JA; June CH; Martin PJ; Spooner CE; Hansen JA; Meier KE
J Immunol; 1986 Jun; 136(11):3945-52. PubMed ID: 3084650
[TBL] [Abstract][Full Text] [Related]
7. Comparison of IgG and F(ab')2 fragments of bispecific anti-RCCxanti-DTIn-1 antibody for pretargeting purposes.
van Schaijk FG; Boerman OC; Soede AC; McBride WJ; Goldenberg DM; Corstens FH; Oosterwijk E
Eur J Nucl Med Mol Imaging; 2005 Sep; 32(9):1089-95. PubMed ID: 15902440
[TBL] [Abstract][Full Text] [Related]
8. The strength of small: improved targeting of insulin-like growth factor-1 receptor (IGF-1R) with F(ab')₂-R1507 fragments in Ewing sarcomas.
Fleuren ED; Versleijen-Jonkers YM; Heskamp S; Roeffen MH; Bouwman WH; Molkenboer-Kuenen JD; van Laarhoven HW; Oyen WJ; Boerman OC; van der Graaf WT
Eur J Cancer; 2013 Sep; 49(13):2851-8. PubMed ID: 23664098
[TBL] [Abstract][Full Text] [Related]
9. Targeted drug delivery via caveolae-associated protein PV1 improves lung fibrosis.
Marchetti GM; Burwell TJ; Peterson NC; Cann JA; Hanna RN; Li Q; Ongstad EL; Boyd JT; Kennedy MA; Zhao W; Rickert KW; Grimsby JS; Dall'Acqua WF; Wu H; Tsui P; Borrok MJ; Gupta R
Commun Biol; 2019; 2():92. PubMed ID: 30854484
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Evaluation of
Shi D; Fu W; Tan H; Lin Q; Shi H; Cheng D
Mol Pharm; 2024 Jan; 21(1):303-312. PubMed ID: 38109713
[TBL] [Abstract][Full Text] [Related]
11. Biodistribution properties of (111)indium-labeled C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid humanized 3S193 diabody and F(ab')(2) constructs in a breast carcinoma xenograft model.
Tahtis K; Lee FT; Smyth FE; Power BE; Renner C; Brechbiel MW; Old LJ; Hudson PJ; Scott AM
Clin Cancer Res; 2001 Apr; 7(4):1061-72. PubMed ID: 11309358
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody.
Negri DR; Tosi E; Valota O; Ferrini S; Cambiaggi A; Sforzini S; Silvani A; Ruffini PA; Colnaghi MI; Canevari S
Br J Cancer; 1995 Oct; 72(4):928-33. PubMed ID: 7547242
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and tumor targeting of 131I-labeled F(ab')2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies.
Brouwers A; Mulders P; Oosterwijk E; Buijs W; Corstens F; Boerman O; Oyen W
Cancer Biother Radiopharm; 2004 Aug; 19(4):466-77. PubMed ID: 15453961
[TBL] [Abstract][Full Text] [Related]
14. Engineered Antibody Fragment against the Urokinase Plasminogen Activator for Fast Delineation of Triple-Negative Breast Cancer by Positron Emission Tomography.
Lu W; Cong Y; Yang D; Chen D; Yang G; Wang Y; Van Dort ME; Ross BD; Mazar AP; Chu BB; Hong H
Mol Pharm; 2021 Apr; 18(4):1690-1698. PubMed ID: 33734721
[TBL] [Abstract][Full Text] [Related]
15. Targeting human prostate cancer with 111In-labeled D2B IgG, F(ab')2 and Fab fragments in nude mice with PSMA-expressing xenografts.
Lütje S; van Rij CM; Franssen GM; Fracasso G; Helfrich W; Eek A; Oyen WJ; Colombatti M; Boerman OC
Contrast Media Mol Imaging; 2015; 10(1):28-36. PubMed ID: 24764162
[TBL] [Abstract][Full Text] [Related]
16. Natural antibodies against the immunoglobulin F(ab')2 fragment cause elimination of antigens recognized by the F(ab')2 from the circulation.
Yano S; Kaku S; Suzuki K; Terazaki C; Sakayori T; Kawasaki T; Kawamura K; Sugita Y; Hoshino K; Masuho Y
Eur J Immunol; 1995 Nov; 25(11):3128-33. PubMed ID: 7489753
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the pharmacokinetics, biodistribution and dosimetry of monoclonal antibodies OC125, OV-TL 3, and 139H2 as IgG and F(ab')2 fragments in experimental ovarian cancer.
Molthoff CF; Pinedo HM; Schlüper HM; Nijman HW; Boven E
Br J Cancer; 1992 May; 65(5):677-83. PubMed ID: 1586596
[TBL] [Abstract][Full Text] [Related]
18. Superior localisation and imaging of radiolabelled monoclonal antibody E48 F(ab')2 fragment in xenografts of human squamous cell carcinoma of the head and neck and of the vulva as compared to monoclonal antibody E48 IgG.
Gerretsen M; Quak JJ; Suh JS; van Walsum M; Meijer CJ; Snow GB; van Dongen GA
Br J Cancer; 1991 Jan; 63(1):37-44. PubMed ID: 1989663
[TBL] [Abstract][Full Text] [Related]
19. Comparative localization of murine monoclonal antibody Me1-14 F(ab')2 fragment and whole IgG2a in human glioma xenografts.
Colapinto EV; Humphrey PA; Zalutsky MR; Groothuis DR; Friedman HS; de Tribolet N; Carrel S; Bigner DD
Cancer Res; 1988 Oct; 48(20):5701-7. PubMed ID: 3167830
[TBL] [Abstract][Full Text] [Related]
20. A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo.
Brezski RJ; Kinder M; Grugan KD; Soring KL; Carton J; Greenplate AR; Petley T; Capaldi D; Brosnan K; Emmell E; Watson S; Jordan RE
MAbs; 2014; 6(5):1265-73. PubMed ID: 25517311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
